New treatments for brain cancer or glioblastoma (GBM), are being studied in Detroit.  

Instead of just one therapy, the trials use an adaptive technology that allows simultaneous evaluation of two or more therapies, or combinations of treatments from various pharmaceutical partners.

GBM AGILE, or Adaptive Global Innovative Learning Environment, is a clinical study that aims to speed up the development of new treatments for brain cancer, including immunotherapy and targeted therapies.

Doctors can go forward with therapies that have been proven to be effective swiftly and efficiently. This is because GBM AGILE is unusual in that it is designed to have a fast succession of rolling trials, utilizing shared data and the most recent research findings from each experiment.

The Henry Ford Hermelin Brain Tumor Center, a significant contributor to The Cancer Genome Atlas, contains the world's third-biggest tumor bank, with over 3,000 brain tumor tissue samples and accompanying data for treatments and results. This highlights the incredible contribution that patients make by enabling their tissue samples and information to be saved for future research.

Following Henry Ford's enrollment of the first patient in GBM AGILE, the study was expanded to other patients at about 35 locations around the United States, Canada, Europe, and China.